Search NLS News

Anders Blanck has been CEO of the trade association for the research-based pharmaceutical industry in Sweden (Lif) since 2011, and before that he was deputy CEO since 2005. Blanck will continue as CEO this fall in order to give the Board time to find a successor. “I am both very grateful and proud of what […]

The Board of Directors has appointed Professor Börje Haraldsson as CEO of the company. “I and the Board as a whole are delighted that Börje Haraldsson is expanding his involvement in Oncorena and takes on the role as CEO of the company. Oncorena is now entering a dynamic clinical phase where all R&D aspects will […]

The Swedish biopharmaceutical company has announced the appointment of two new members to its Board of Directors, Tara Heitner and Pete Zorn. “We are excited to welcome Tara and Pete to our Board,” says Adam Bruce, Founder and Chairman of the Board of TikoMed in a press release. “Tara and Pete are perfect fits for […]

The company’s CEO, Anders Månsson, announced in July his wish to leave his position with the company no later than after the 3-month stipulated notice period. “I wish Anders Månsson all the best in his new endeavours and sincerely thank him for his period as CEO of RhoVac. Anders did an excellent job, not least […]

Scientists at deCODE genetics together with collaborators from Denmark report on the whole genome sequences of 150 thousand participants in the UK biobank in a paper published in the journal Nature. This is the first report from the largest whole genome sequencing effort to date where scientists from deCODE genetics and the Wellcome Trust Sanger […]

The Board of Directors of IRLAB has appointed its current CEO, Nicholas Waters, to the role of Executive Vice President and Head of Research & Development and recruited Richard Godfrey as the new CEO. “With the new management structure and the recruitment of Richard Godfrey, we are strengthening our resources and expertise in both the […]

The company’s Phase 1 clinical safety study on the drug candidate AQ280 on healthy volunteers has started. The substance AQ280, part of the company’s Regulus development program, is a super selective JAK1 small molecule inhibitor that is under development for indications within chronic inflammatory diseases. Aqilion has thus reached a very important milestone as the […]

Isofol Medical has announced that neither the primary endpoint of Overall Response Rate (ORR) nor the key secondary endpoint in Progression Free Survival (PFS) achieved statistical significance in the multi-center, international Phase III AGENT Study of arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in metastatic colorectal cancer (mCRC). The AGENT Study is the first […]

A variant typical of the Finnish population that protects against heart diseases was identified in the FinnGen genomic study coordinated by the University of Helsinki. The risk of developing heart diseases is roughly one-fifth lower in carriers of the variant compared to the population on average. The protective effect of the newly discovered variant against […]

Earlier this summer the company won the Life Science Business Award of the city (Malmö Näringslivspris Life Science). The jury stressed the important role of PolyPeptide as part of Malmö’s Life Science cluster, recognizing the continued growth and positive developments as a high-quality, responsible employer. “I would like to thank all the employees: The award […]